ADVERTISEMENT
Biomimetic Transcatheter Aortic Heart Valve Offers New Option for Aortic Stenosis Patients
DurAVRTM Transcatheter Heart Valve Built to Mimic the Performance of a Healthy Aortic Valve
DurAVRTM Transcatheter Heart Valve Built to Mimic the Performance of a Healthy Aortic Valve
Long Beach, Calif. – Recent findings from a study on a transcatheter heart valve (THV) system, which includes a new class of transcatheter aortic valve, showed positive results in the device's ability to function as a healthy and natural aortic valve in patients with aortic stenosis (AS). The late-breaking data will be presented today at the Society for Cardiovascular Angiography & Interventions (SCAI) 2024 Scientific Sessions.
A prospective non-randomized, single-arm, single-center, First-in-Human (FIH) study of 28 patients, was designed to evaluate safety and feasibility in patients with severe symptomatic AS with the DurAVR™ Transcatheter Heart Valve (THV) System from Anteris Technologies. Clinical, echo, computerized tomography (CT), and cardiac MRI assessments were performed for up to one year.
The DurAVR™ valve was successfully implanted in 100% of the cases. All patients showed excellent post-procedural hemodynamic results, despite a small mean annulus size. No moderate or severe paravalvular leak was observed. Additionally, laminar flow was consistently displayed on cardiac MRI. For those patients at 12-month follow-up, the valve also showed a favorable safety profile in all patients and no valve-related complications, strokes, life-threatening bleeding, or reoperations occurred.
“We are excited to share such favorable results early on in our trial as it represents a novel option for TAVR procedures by providing encouraging evidence of improved hemodynamics and normalized blood flow characteristics associated with the system,” said Azeem Latib, MD, Director of Interventional Cardiology and Structural Heart Interventions at Montefiore Medical Center in New York. “We look forward to sharing additional results that support the valve performance characteristics and how similar they are to the ones of a healthy aortic valve.”
Additional testing on the DurAVR™ THV System is currently underway, and more data is expected to be presented this year.
Session Details:
- “Update from the First-in-human study with the novel DurAVR biomimetic transcatheter heart valve”
- Thursday, May 3, 2024; 2:50-2:57 PM PT
- Long Beach Convention Center, 104A, First Level
About Society for Cardiovascular Angiography & Interventions (SCAI)
The Society for Cardiovascular Angiography & Interventions, established in 1978, stands as the primary nonprofit medical society dedicated to representing invasive and interventional cardiology. SCAI's mission is to guide the global interventional cardiovascular community by fostering education, advocacy, research, and upholding standards for quality patient care. For more than 40 years, SCAI has exemplified professional excellence and innovation worldwide, cultivating a reputable community of over 4,500 members committed to advancing medical science and providing life-saving care for individuals, both adults and children, affected by cardiovascular disease. For more information, visit https://scai.org/.
For more information about the SCAI 2024 Scientific Sessions, visit https://scai.org/scai-2024-scientific-sessions. Follow @SCAI on X (formerly Twitter) and on LinkedIn for the latest heart health news and use #SCAI2024 to follow the latest discussions.
Find More:
The Latest Clinical & Industry News
Grand Rounds With Morton Kern, MD
